MDxHealth S.A.

NASDAQ:MDXH

Medical - Diagnostics & Research

Healthcare
$0.60 -4.45%

-$0.03 today

Market cap
$57.59M
Beta
0.38
P/E (TTM)
-1.0
EPS (TTM)
-$0.58
52W Low $0.40High $5.33

Volume 0.65M

Average 4.27M

MDXH Interest Expense

Cost of servicing the company's debt during the period.

MDxHealth S.A.NASDAQ: MDXH

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense declines year over year

Q2 FY2026 interest expense of $6.08M fell 3.4% year over year. Over 3 fiscal years it compounded at +64.3% a year.

Context

  • Interest expense amounted to 11.3% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.08M— QoQ
Last fiscal yearDec 2025
$12.16M+59.4% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.4%——
1 year+59.4%——
3-year CAGR+64.3%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
12.16M USD
Year-over-year change
+59.4%
4-year CAGR
+59.6%

Interest Expense vs competitors

How MDXH compares with its peers on the latest reported figures

  • MDXH's FY2025 interest expense of $12.16M is the highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of +59.4% is the 2nd highest of 5, against a peer median of -57.1%.
  • Interest expense amounts to 11.3% of revenue for MDXH, versus a peer median of 0.2%.
MDXH Competitors Peer median
Interest Expense for MDXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDXHMDxHealth S.A.FY2025$12.16M +59.4%+64.3%11.3%
XGNExagen Inc.LTM Mar 2026$5.04M +126.0%+20.8%7.4%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$4.94M -58.6%-23.8%11.1%
NEONeoGenomics, Inc.LTM Jun 2026$2.58M -55.6%-20.9%0.3%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$0 ——0.0%
ZURAZura Bio LimitedLTM Mar 2026$0 ———
IMRXImmuneering CorporationLTM Mar 2026$0 ———
QTRXQuanterix CorporationLTM Mar 2026$0 ——0.0%
STXSStereotaxis, Inc.LTM Mar 2026$0 ——0.0%
SIShoulder Innovations, Inc.LTM Mar 2026-$733K -153.7%—1.4%
Peer median (excluding MDXH) $0-57.1%-20.9%0.2%

Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue22.24M37.05M70.19M90.05M107.88M
Cost of Revenue11.68M17.84M26.26M34.91M43.43M
Gross Profit10.56M19.22M43.93M55.14M64.44M
Gross Margin47.5%51.9%62.6%61.2%59.7%
Research & Development5.59M7.56M6.38M10.55M10.35M
Selling, General & Admin30.22M50.12M59.93M61.4M66.75M
Operating Expenses37.41M57.12M71.26M79.86M79.84M
Depreciation & Amortization3.04M4.91M6.86M8.04M9.21M
EBITDA(24.09M)(36.39M)(30.47M)(22.02M)(14.01M)
EBITDA Margin-108.3%-98.2%-43.4%-24.5%-13.0%
Operating Income(26.84M)(37.9M)(27.33M)(24.72M)(15.4M)
Operating Margin-120.7%-102.3%-38.9%-27.5%-14.3%
Interest Income11K125K1.09M1.08M1.5M
Interest Expense1.88M2.74M5.77M7.63M12.16M
Other Income / Expenses(2.16M)(6.14M)(15.77M)(12.97M)(19.98M)
Income Before Tax(29M)(44.04M)(43.1M)(37.69M)(35.38M)
Pre-Tax Margin-130.4%-118.9%-61.4%-41.9%-32.8%
Income Tax Expense001K382K(1.86M)
Net Income(29M)(44.04M)(43.1M)(38.07M)(33.52M)
Net Margin-130.4%-118.9%-61.4%-42.3%-31.1%
EPS (Basic)(2.38)(2.78)(1.66)(0.78)(0.67)
EPS (Diluted)(2.38)(2.78)(1.66)(1.16)(0.67)
Weighted Avg Shares12.19M15.87M25.91M48.67M50.03M
Weighted Avg Shares (Diluted)12.19M15.87M25.91M48.67M50.03M

MDxHealth S.A.

NASDAQ:MDXH

Intrinsic Alpha fair value

Locked

Current Price

$0.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.